Nasdaq

Entheon Biomedical Announces Investment and Business Arrangement with Heading Health LLC

Vancouver, British Columbia--(Newsfile Corp. - January 4, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing ...
Yahoo Finance

Entheon Biomedical Announces Sponsorship of a Clinical Study to Assess the Electroneurophysiologic Effects of Ketamine

Vancouver, British Columbia--(Newsfile Corp. - August 12, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a ...
Yahoo Finance

Entheon Biomedical Provides Corporate Update on Studies and Clinical Trials

Vancouver, British Columbia--(Newsfile Corp. - October 27, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a ...
TipRanks on MSN

Entheon to pivot into nutraceuticals with $40 million Nutravisor acquisition

Entheon Biomedical ( ($TSE:ENBI) ) just unveiled an announcement. Entheon Biomedical has signed a binding letter of intent to acquire all of the ...
Benzinga.com

Entheon Biomedical Acquires Lobo Genetics, Inc. in Bid to Strengthen Screening and Treatment Evaluation Tech for Psychedelics

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Entheon Biomedical Corp. ENTBF, the biotech ...
Nasdaq

Entheon Biomedical Provides Update on Centre for Human Drug Research License Amendments

Vancouver, British Columbia--(Newsfile Corp. - February 2, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on ...
Stockhouse

Entheon Announces Sale of Certain DMT Clinical Assets and Filing of Provisional Novel Compound Patents

Vancouver, British Columbia--(Newsfile Corp. - June 7, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company") today announced that it has entered into a ...
The Globe and Mail

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) Featured in Virtual Coverage of Benzinga’s Small Cap Conference

Entheon Biomedical (CSE: ENBI) (OTCQB: ENTBF) is researching and developing psychedelic drugs for the treatment of addiction disorders. With a focus on the psychedelic DMT molecule, Entheon’s upcoming ...
Benzinga.com

Entheon Biomedical Stock Price, Quotes and Forecasts | OTC:ENTBF | Benzinga

Explore Entheon Biomedical stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for ENTBF. World Class Leaders In Psychedelics Form Benzinga's Psychedelic Advisory ...
Mena FN

Entheon Biomedical Announces CRO Agreement with CHDR for Phase 1 Clinical Trial Centre for Human Drug Research Led DMT Study to Start in 2021

(MENAFN- Newsfile Corp) Entheon Biomedical Announces CRO Agreement with CHDR for Phase 1 Clinical Trial; Centre for Human Drug Research Led DMT Study to Start in 2021 Vancouver, British ...
Finanznachrichten

Entheon Biomedical Corp.: Entheon Biomedical Announces EEG Patent Application & Provides Research Update

Vancouver, British Columbia--(Newsfile Corp. - December 16, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the ...